MAP plots funding route to US Levadex launch
This article was originally published in Scrip
Executive Summary
MAP Pharmaceuticals appears optimistic about its chances of winning US FDA approval for Levadex (dihydroergotamine) after receiving a complete response letter (CRL) from the agency earlier this year, since the company has initiated a common stock offering to raise $52 million that it plans to spend on commercialising its inhaled migraine therapy.